COVID‐19: vaccination problems
Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vac...
Saved in:
| Published in | Environmental microbiology Vol. 23; no. 6; pp. 2878 - 2890 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.06.2021
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1462-2912 1462-2920 1462-2920 |
| DOI | 10.1111/1462-2920.15549 |
Cover
| Abstract | Summary
This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned. |
|---|---|
| AbstractList | This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned. This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned.This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned. Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned. |
| Author | Brüssow, Harald |
| AuthorAffiliation | 1 Department of Biosystems Laboratory of Gene Technology, KU Leuven Leuven Belgium |
| AuthorAffiliation_xml | – name: 1 Department of Biosystems Laboratory of Gene Technology, KU Leuven Leuven Belgium |
| Author_xml | – sequence: 1 givenname: Harald orcidid: 0000-0003-4783-8583 surname: Brüssow fullname: Brüssow, Harald email: haraldbruessow@yahoo.com organization: Laboratory of Gene Technology, KU Leuven |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33928745$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFOAjEURRuDEVDX7gyJGzdo22lL68LEICoJho26bTrljZYMU5wChp2f4Df6JRZBoiSG2XTannvf67t1VCl8AQgdEXxG4ndOmKBNqmjccs7UDqqtTyrrf0KrqB7CEGPSSlp4D1WTRFHZYryGGu3-U_f68_2DqIvGzFjrCjNxvmiMS5_mMAoHaDczeYDD1bqPHm86D-27Zq9_221f9ZqWU6maMOBcAleZVUZYaoQ0TElrWGZIhimAYik1BCdABjhlIAUdCJMaYFkqFObJPrpc-o6n6QgGFopJaXI9Lt3IlHPtjdN_bwr3op_9TEuKlZQyGpyuDEr_OoUw0SMXLOS5KcBPg6ZCxPIkocl2lFMsFVaCRfRkAx36aVnESUSKCRwLJ4vmj383v-76Z84R4EvAlj6EEjJt3eR70PEtLtcE60WeepGYXqSnv_OMuvMN3Y_1_4pVpTeXw3wbrjv33aXuC4N4rm0 |
| CitedBy_id | crossref_primary_10_1016_j_intimp_2021_108162 crossref_primary_10_1016_j_clineuro_2024_108183 crossref_primary_10_1136_bmjopen_2023_073914 crossref_primary_10_1016_j_cie_2023_109465 crossref_primary_10_7759_cureus_29276 crossref_primary_10_1016_j_asoc_2022_109801 crossref_primary_10_3389_fimmu_2022_1053617 crossref_primary_10_3389_fmed_2022_800962 crossref_primary_10_5005_jacm_11020_0002 crossref_primary_10_1002_ski2_139 crossref_primary_10_1186_s12879_023_08553_w crossref_primary_10_15283_ijsc24056 crossref_primary_10_3389_fphar_2023_1185076 crossref_primary_10_5662_wjm_v12_i4_200 crossref_primary_10_3389_fpubh_2022_748498 crossref_primary_10_3390_idr15060061 crossref_primary_10_7759_cureus_23526 crossref_primary_10_1016_j_physa_2022_127915 crossref_primary_10_1002_smm2_1274 crossref_primary_10_1007_s00894_022_05391_6 crossref_primary_10_3892_br_2024_1766 crossref_primary_10_4103_aian_aian_669_21 crossref_primary_10_1136_bmjopen_2024_086539 crossref_primary_10_1002_ptr_7554 crossref_primary_10_31631_2073_3046_2022_21_4_113_118 crossref_primary_10_1016_j_cca_2021_09_022 crossref_primary_10_3389_fpubh_2022_951096 crossref_primary_10_3390_computation10060086 crossref_primary_10_2196_44664 crossref_primary_10_1111_1462_2920_16201 crossref_primary_10_3390_biomedicines11082191 crossref_primary_10_61182_rnavmed_v8n1a5 crossref_primary_10_1097_MS9_0000000000000921 crossref_primary_10_3390_biology10100960 crossref_primary_10_3390_vaccines11091496 crossref_primary_10_3389_fpubh_2022_914121 crossref_primary_10_1097_JCMA_0000000000000612 crossref_primary_10_14202_vetworld_2024_1281_1290 crossref_primary_10_2174_1871530322666220621101209 crossref_primary_10_19163_2307_9266_2023_11_1_72_88 crossref_primary_10_3389_fimmu_2024_1382619 crossref_primary_10_1186_s12939_024_02110_w crossref_primary_10_3390_vaccines9101052 crossref_primary_10_1111_1751_7915_13945 crossref_primary_10_1155_2022_3392667 crossref_primary_10_26442_00403660_2022_11_201980 crossref_primary_10_3346_jkms_2022_37_e44 crossref_primary_10_1016_j_jcpo_2024_100486 |
| Cites_doi | 10.1038/s41591-021-01318-5 10.1056/NEJMp2033538 10.1001/jama.2021.5374 10.1038/s41586-021-03324-6 10.1126/science.abe2803 10.1038/s41591-021-01230-y 10.1056/NEJMclde2101987 10.1016/S1473-3099(21)00008-6 10.1056/NEJMc2101667 10.1038/d41586-021-00940-0 10.1101/2021.01.25.427948 10.1056/NEJMp2034765 10.1056/NEJMc2105869 10.1038/d41586-021-00001-6 10.1056/NEJMc2102179 10.1101/2021.01.28.428665 10.1016/S0140-6736(21)00306-8 10.1038/d41586-020-03441-8 10.1056/NEJMra2035343 10.1126/science.abg2334 10.1056/NEJMoa2104882 10.1016/j.cell.2021.03.013 10.1001/jama.2021.0600 10.15585/mmwr.mm6947e3 10.1126/science.abg0889 10.1056/NEJMc2106075 10.1001/jama.2021.1967 10.1056/NEJMms2033790 10.1126/science.abf5084 10.1126/science.abg5655 10.1016/S1473-3099(21)00057-8 10.1073/pnas.2025786118 10.1038/d41586-021-00315-5 10.1016/S0140-6736(21)00501-8 10.1126/science.370.6520.1022 10.1056/NEJMoa2105385 10.1016/S0140-6736(20)32642-8 10.1056/NEJMc2103916 10.1001/jama.2020.25384 10.1126/science.371.6525.109 10.1056/NEJMc2102017 10.1016/S0140-6736(21)00455-4 10.1038/s41591-021-01270-4 10.1126/science.abg6105 10.1001/jama.2016.4218 10.1038/d41586-020-03542-4 10.1016/S1473-3099(20)30476-X 10.1093/infdis/jiy639 10.1126/science.abf0357 10.1016/S2213-2600(20)30518-X 10.1038/d41586-021-00996-y 10.1016/j.cell.2021.02.037 10.1038/d41586-020-02821-4 10.1086/603560 10.1101/2021.03.01.21252652 10.1038/d41586-021-00015-0 10.1016/j.chom.2021.03.009 10.1038/s41586-021-03398-2 10.1056/NEJMc2104036 10.15585/mmwr.mm695152e2 10.1016/S1473-3099(15)00362-X 10.1016/S0140-6736(21)00432-3 10.1056/NEJMoa2104840 10.1056/NEJMc2102131 10.1126/science.abe6959 |
| ContentType | Journal Article |
| Copyright | 2021 Society for Applied Microbiology and John Wiley & Sons Ltd. 2021 Society for Applied Microbiology and John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2021 Society for Applied Microbiology and John Wiley & Sons Ltd. – notice: 2021 Society for Applied Microbiology and John Wiley & Sons Ltd |
| DBID | AAYXX CITATION NPM 7QH 7QL 7ST 7T7 7TN 7U9 7UA 8FD C1K F1W FR3 H94 H95 H97 L.G M7N P64 SOI 7X8 7S9 L.6 5PM |
| DOI | 10.1111/1462-2920.15549 |
| DatabaseName | CrossRef PubMed Aqualine Bacteriology Abstracts (Microbiology B) Environment Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Oceanic Abstracts Virology and AIDS Abstracts Water Resources Abstracts Technology Research Database Environmental Sciences and Pollution Management ASFA: Aquatic Sciences and Fisheries Abstracts Engineering Research Database AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Environment Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Aquatic Science & Fisheries Abstracts (ASFA) Professional Virology and AIDS Abstracts Technology Research Database Aqualine Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Water Resources Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Oceanic Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) ASFA: Aquatic Sciences and Fisheries Abstracts AIDS and Cancer Research Abstracts Engineering Research Database Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Industrial and Applied Microbiology Abstracts (Microbiology A) Environment Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Aquatic Science & Fisheries Abstracts (ASFA) Professional AGRICOLA MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | COVID‐19 Vaccination problems |
| EISSN | 1462-2920 |
| EndPage | 2890 |
| ExternalDocumentID | PMC8209888 33928745 10_1111_1462_2920_15549 EMI15549 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHBH AAHQN AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ACAHQ ACBWZ ACCZN ACFBH ACGFO ACGFS ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIAGR AIDQK AIDYY AITYG AIURR AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 C45 CAG COF CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBS ECGQY EJD F00 F01 F04 F5P FEDTE G-S G.N GODZA H.T H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ O66 O9- OBS OIG OVD P2P P2W P2X P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 V8K W8V W99 WBKPD WIH WIK WNSPC WOHZO WQJ WXSBR WYISQ XG1 XIH YUY ZZTAW ~02 ~IA ~KM ~WT AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION NPM 7QH 7QL 7ST 7T7 7TN 7U9 7UA 8FD C1K F1W FR3 H94 H95 H97 L.G M7N P64 SOI 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c5289-ed558e59fc9a6c2a68a498ca4fa1f02ee94b2a103e1d0b4e862d6abae4fb69053 |
| IEDL.DBID | DR2 |
| ISSN | 1462-2912 1462-2920 |
| IngestDate | Thu Aug 21 18:18:43 EDT 2025 Fri Jul 11 18:27:35 EDT 2025 Fri Jul 11 05:38:01 EDT 2025 Fri Jul 25 12:29:02 EDT 2025 Thu Apr 03 06:53:25 EDT 2025 Tue Jul 01 04:00:47 EDT 2025 Thu Apr 24 22:52:24 EDT 2025 Sun Jul 06 04:45:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | 2021 Society for Applied Microbiology and John Wiley & Sons Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5289-ed558e59fc9a6c2a68a498ca4fa1f02ee94b2a103e1d0b4e862d6abae4fb69053 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-4783-8583 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8209888 |
| PMID | 33928745 |
| PQID | 2546088335 |
| PQPubID | 1066360 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8209888 proquest_miscellaneous_2661031323 proquest_miscellaneous_2520890964 proquest_journals_2546088335 pubmed_primary_33928745 crossref_citationtrail_10_1111_1462_2920_15549 crossref_primary_10_1111_1462_2920_15549 wiley_primary_10_1111_1462_2920_15549_EMI15549 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2021 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: England – name: Oxford |
| PublicationTitle | Environmental microbiology |
| PublicationTitleAlternate | Environ Microbiol |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
| References | 2021; 69 2021a; 589 2021b; 590 2021a; 588 2021; 27 2021; 29 2021; 589 2021; 325 2020; 369 2020; 588 2021; 184 2021b 2021a 2021; 384 2021c; 592 2020; 586 2016; 16 2020; 8 2021b; 21 2021b; 384 2021a; 592 2021 2020 2020a; 588 2020; 370 2021a; 370 2021; 118 2021; 371 2009; 200 2020; 69 2016; 315 2020; 397 2021; 592 2019; 219 2020b; 588 2021; 397 2020; 21 e_1_2_11_70_1 e_1_2_11_72_1 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_74_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 Anonymous (e_1_2_11_3_1) 2021; 588 e_1_2_11_60_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_66_1 e_1_2_11_47_1 e_1_2_11_68_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_64_1 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_59_1 e_1_2_11_38_1 e_1_2_11_19_1 e_1_2_11_50_1 e_1_2_11_71_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_58_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_49_1 e_1_2_11_61_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_18_1 Anonymus (e_1_2_11_2_1) 2020; 588 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 |
| References_xml | – volume: 384 start-page: 643 year: 2021 end-page: 649 article-title: Maintaining safety with SARS‐CoV‐2 vaccines. 2020 publication-title: N Engl J Med – volume: 588 start-page: 195 year: 2020 article-title: Eyes of the world are on medicines regulators publication-title: Nature – volume: 371 start-page: 916 year: 2021 end-page: 921 article-title: Model‐informed COVID‐19 vaccine prioritization strategies by age and serostatus publication-title: Science – volume: 29 start-page: 516 year: 2021 end-page: 521.e3 article-title: Infection‐ and vaccine‐induced antibody binding and neutralization of the B.1.351 SARS‐CoV‐2 variant publication-title: Cell Host Microbe – year: 2021 article-title: Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV‐19 vaccination publication-title: N Engl J Med – volume: 69 start-page: 1782 year: 2020 end-page: 1786 article-title: The advisory committee on immunization practices' ethical principles for allocating initial supplies of COVID‐19 vaccine—United States, 2020 publication-title: Morb Mortal Wkly Rep – volume: 200 start-page: 321 year: 2009 end-page: 328 article-title: "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain‐Barré syndrome, and the detection of rare severe adverse events publication-title: J Infect Dis – year: 2021 – volume: 16 start-page: 31 year: 2016 end-page: 42 article-title: Use of ChAd3‐EBO‐Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA‐BN‐filo: a phase 1, single‐blind, randomised trial, a phase 1b, open‐label and double‐blind, dose‐escalation trial, and a nested, randomised, double‐blind, placebo‐controlled trial. 2016 publication-title: Lancet Infect Dis – volume: 384 year: 2021 article-title: Beyond politics ‐ promoting Covid‐19 vaccination in the United States publication-title: N Engl J Med – volume: 184 year: 2021 article-title: Multiple SARS‐CoV‐2 variants escape neutralization by vaccine‐induced humoral immunity publication-title: Cell – year: 2021 article-title: Antibody persistence through 6 months after the second dose of mRNA‐1273 vaccine for Covid‐19 publication-title: N Engl J Med – year: 2021 article-title: Neutralizing response against variants after SARS‐CoV‐2 infection and one dose of BNT162b2 publication-title: N Engl J Med – volume: 325 start-page: 1101 year: 2021 end-page: 1102 article-title: Reports of anaphylaxis after receipt of mRNA COVID‐19 vaccines in the US‐December 14, 2020‐January 18, 2021 publication-title: JAMA – volume: 384 start-page: 1273 year: 2021 end-page: 1277 article-title: Delayed large local reactions to mRNA‐1273 vaccine against SARS‐CoV‐2 publication-title: N Engl J Med – year: 2021 article-title: Thrombosis and thrombocytopenia after ChAdOx1 nCoV‐19 vaccination publication-title: N Engl J Med – volume: 589 start-page: 340 year: 2021 end-page: 341 article-title: Search for better COVID vaccines confounded by existing rollouts publication-title: Nature – year: 2021 article-title: Thrombotic thrombocytopenia after Ad26.COV2.S vaccination—response from the manufacturer publication-title: N Engl J Med – volume: 592 start-page: 334 year: 2021c end-page: 335 article-title: How could a COVID vaccine cause blood clots? Scientists race to investigate publication-title: Nature – volume: 219 start-page: 1187 year: 2019 end-page: 1197 article-title: Safety and immunogenicity of a heterologous prime‐boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal publication-title: J Infect Dis – volume: 397 start-page: 881 year: 2021 end-page: 891 article-title: Single‐dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV‐19 (AZD1222) vaccine: a pooled analysis of four randomised trials publication-title: Lancet – volume: 184 start-page: 2348 year: 2021 end-page: 2361.e6 article-title: Evidence of escape of SARS‐CoV‐2 variant B.1.351 from natural and vaccine induced sera publication-title: Cell – year: 2021a – volume: 370 start-page: 1274 year: 2020 end-page: 1275 article-title: Ensuring vaccine safety publication-title: Science – volume: 69 start-page: 1657 year: 2021 end-page: 1660 article-title: The advisory committee on immunization Practices' updated interim recommendation for allocation of COVID‐19 vaccine—United States, December 2020 publication-title: Morb Mortal Wkly Rep – volume: 325 start-page: 780 year: 2021 end-page: 781 article-title: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine publication-title: JAMA – volume: 384 start-page: 1372 year: 2021 end-page: 1374 article-title: Antibody responses in seropositive persons after a single dose of SARS‐CoV‐2 mRNA vaccine publication-title: N Engl J Med – volume: 384 year: 2021 article-title: Placebo‐controlled trials of Covid‐19 vaccines—why we still need them publication-title: N Engl J Med – volume: 589 start-page: 182 year: 2021a article-title: How can countries stretch COVID vaccine supplies? Scientists are divided over dosing strategies publication-title: Nature – volume: 27 start-page: 620 year: 2021 end-page: 621 article-title: Neutralization of SARS‐CoV‐2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine‐elicited sera publication-title: Nat Med – volume: 371 start-page: 890 year: 2021 end-page: 891 article-title: Optimizing age‐specific vaccination publication-title: Science – volume: 588 start-page: 205 year: 2020a end-page: 206 article-title: The UK has approved a COVID vaccine—here's what scientists now want to know publication-title: Nature – volume: 384 start-page: 589 year: 2021 end-page: 591 article-title: Vaccinating children against Covid‐19—the lessons of measles. 2021 publication-title: N Engl J Med – volume: 592 start-page: 616 year: 2021a end-page: 622 article-title: mRNA vaccine‐elicited antibodies to SARS‐CoV‐2 and circulating variants publication-title: Nature – volume: 370 start-page: 1277 year: 2020 end-page: 1279 article-title: COVID‐19 vaccine trial ethics once we have efficacious vaccines publication-title: Science – volume: 384 year: 2021 article-title: Neutralizing activity of BNT162b2‐elicited serum publication-title: N Engl J Med – volume: 21 start-page: 149 year: 2021b article-title: An exceptional vaccination policy in exceptional circumstances publication-title: Lancet Infect Dis – year: 2021 article-title: Thrombotic thrombocytopenia after Ad26.COV2.S vaccination publication-title: N Engl J Med – year: 2021b article-title: Antibody resistance of SARS‐CoV‐2 variants B.1.351 and B.1.1.7. 2021 publication-title: Nature – volume: 27 start-page: 205 year: 2021 end-page: 211 article-title: Looking beyond COVID‐19 vaccine phase 3 trials publication-title: Nat Med – volume: 397 start-page: 1057 year: 2021 end-page: 1058 article-title: Antibody response to first BNT162b2 dose in previously SARS‐CoV‐2‐infected individuals publication-title: Lancet – volume: 371 start-page: 1107 year: 2021 end-page: 1109 article-title: Market design to accelerate COVID‐19 vaccine supply publication-title: Science – volume: 315 start-page: 1610 year: 2016 end-page: 1623 article-title: Safety and immunogenicity of novel adenovirus type 26‐ and modified vaccinia Ankara‐vectored Ebola vaccines: a randomized clinical trial publication-title: JAMA – volume: 325 start-page: 825 year: 2021 end-page: 826 article-title: Funding of pharmaceutical innovation during and after the COVID‐19 pandemic publication-title: JAMA – volume: 118 year: 2021 article-title: Dynamic prioritization of COVID‐19 vaccines when social distancing is limited for essential workers publication-title: Proc Natl Acad Sci U S A – volume: 8 year: 2020 article-title: COVID‐19 human challenge studies in the UK. 2020 publication-title: Lancet Respir Med – volume: 371 start-page: 1152 year: 2021 end-page: 1153 article-title: Neutralization of SARS‐CoV‐2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine‐elicited human sera publication-title: Science – volume: 21 start-page: 493 year: 2020 end-page: 506 article-title: Safety and immunogenicity of a two‐dose heterologous Ad26.ZEBOV and MVA‐BN‐Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer‐blind, participant‐blind, placebo‐controlled, phase 2 trial publication-title: Lancet Infect Dis – volume: 588 start-page: 377 year: 2020b end-page: 378 article-title: US authorization of first COVID vaccine marks new phase in safety monitoring publication-title: Nature – volume: 590 start-page: 375 year: 2021b end-page: 376 article-title: Could mixing COVID vaccines boost immune response? publication-title: Nature – volume: 369 start-page: 1309 year: 2020 end-page: 1312 article-title: An ethical framework for global vaccine allocation publication-title: Science – year: 2021 article-title: Prioritising COVID‐19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study publication-title: Lancet Infect Dis – year: 2021 article-title: Reactogenicity following receipt of mRNA‐based COVID‐19 vaccines publication-title: JAMA – volume: 370 start-page: 1022 year: 2021a article-title: Public needs to prep for vaccine side effects publication-title: Science – year: 2021 article-title: Sensitivity of infectious SARS‐CoV‐2 B.1.1.7 and B.1.351 variants to neutralizing antibodies publication-title: Nat Med – volume: 592 start-page: 500 year: 2021 end-page: 501 article-title: India's COVID‐vaccine woes ‐ by the numbers publication-title: Nature – volume: 588 start-page: 195 year: 2021a article-title: Science advisers: publish evidence behind COVID vaccine dosing strategy publication-title: Nature – year: 2021b – volume: 586 start-page: 651 year: 2020 end-page: 652 article-title: Dozens to be deliberately infected with coronavirus in UK'human challenge' trials publication-title: Nature – volume: 384 start-page: 1468 year: 2021b end-page: 1470 article-title: Serum neutralizing activity elicited by mRNA‐1273 vaccine—preliminary report publication-title: N Engl J Med – volume: 371 start-page: 109 year: 2021 end-page: 110 article-title: Dosing debates, transparency issues roil vaccine rollouts publication-title: Science – year: 2020 – volume: 384 year: 2021 article-title: Delayed second dose versus standard regimen for Covid‐19 vaccination publication-title: N Engl J Med – volume: 397 start-page: 879 year: 2021 end-page: 880 article-title: Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? publication-title: Lancet – year: 2021 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov‐19 vaccination publication-title: N Engl J Med – volume: 397 start-page: 1023 year: 2021 end-page: 1034 article-title: Challenges in ensuring global access to COVID‐19 vaccines: production, affordability, allocation, and deployment publication-title: Lancet – volume: 397 start-page: 8 year: 2020 end-page: 10 article-title: The COVID‐19 vaccines rush: participatory community engagement matters more than ever publication-title: Lancet – ident: e_1_2_11_49_1 doi: 10.1038/s41591-021-01318-5 – ident: e_1_2_11_35_1 doi: 10.1056/NEJMp2033538 – ident: e_1_2_11_15_1 doi: 10.1001/jama.2021.5374 – ident: e_1_2_11_66_1 doi: 10.1038/s41586-021-03324-6 – ident: e_1_2_11_23_1 doi: 10.1126/science.abe2803 – ident: e_1_2_11_30_1 doi: 10.1038/s41591-021-01230-y – ident: e_1_2_11_29_1 doi: 10.1056/NEJMclde2101987 – ident: e_1_2_11_4_1 doi: 10.1016/S1473-3099(21)00008-6 – ident: e_1_2_11_34_1 doi: 10.1056/NEJMc2101667 – ident: e_1_2_11_40_1 doi: 10.1038/d41586-021-00940-0 – volume: 588 start-page: 195 year: 2021 ident: e_1_2_11_3_1 article-title: Science advisers: publish evidence behind COVID vaccine dosing strategy publication-title: Nature – ident: e_1_2_11_72_1 doi: 10.1101/2021.01.25.427948 – ident: e_1_2_11_32_1 doi: 10.1056/NEJMp2034765 – ident: e_1_2_11_47_1 doi: 10.1056/NEJMc2105869 – ident: e_1_2_11_38_1 doi: 10.1038/d41586-021-00001-6 – ident: e_1_2_11_71_1 doi: 10.1056/NEJMc2102179 – ident: e_1_2_11_59_1 doi: 10.1101/2021.01.28.428665 – ident: e_1_2_11_70_1 doi: 10.1016/S0140-6736(21)00306-8 – ident: e_1_2_11_36_1 doi: 10.1038/d41586-020-03441-8 – ident: e_1_2_11_11_1 doi: 10.1056/NEJMra2035343 – ident: e_1_2_11_25_1 doi: 10.1126/science.abg2334 – ident: e_1_2_11_55_1 doi: 10.1056/NEJMoa2104882 – ident: e_1_2_11_26_1 doi: 10.1016/j.cell.2021.03.013 – ident: e_1_2_11_58_1 doi: 10.1001/jama.2021.0600 – ident: e_1_2_11_68_1 – ident: e_1_2_11_44_1 doi: 10.15585/mmwr.mm6947e3 – ident: e_1_2_11_12_1 doi: 10.1126/science.abg0889 – ident: e_1_2_11_54_1 doi: 10.1056/NEJMc2106075 – ident: e_1_2_11_57_1 doi: 10.1001/jama.2021.1967 – ident: e_1_2_11_69_1 doi: 10.1056/NEJMms2033790 – ident: e_1_2_11_67_1 doi: 10.1126/science.abf5084 – ident: e_1_2_11_64_1 doi: 10.1126/science.abg5655 – ident: e_1_2_11_28_1 doi: 10.1016/S1473-3099(21)00057-8 – volume: 588 start-page: 195 year: 2020 ident: e_1_2_11_2_1 article-title: Eyes of the world are on medicines regulators publication-title: Nature – ident: e_1_2_11_8_1 doi: 10.1073/pnas.2025786118 – ident: e_1_2_11_39_1 doi: 10.1038/d41586-021-00315-5 – ident: e_1_2_11_43_1 doi: 10.1016/S0140-6736(21)00501-8 – ident: e_1_2_11_17_1 – ident: e_1_2_11_14_1 – ident: e_1_2_11_63_1 doi: 10.1126/science.370.6520.1022 – ident: e_1_2_11_56_1 doi: 10.1056/NEJMoa2105385 – ident: e_1_2_11_13_1 – ident: e_1_2_11_9_1 doi: 10.1016/S0140-6736(20)32642-8 – ident: e_1_2_11_20_1 doi: 10.1056/NEJMc2103916 – ident: e_1_2_11_53_1 doi: 10.1001/jama.2020.25384 – ident: e_1_2_11_16_1 doi: 10.1126/science.371.6525.109 – ident: e_1_2_11_41_1 doi: 10.1056/NEJMc2102017 – ident: e_1_2_11_52_1 doi: 10.1016/S0140-6736(21)00455-4 – ident: e_1_2_11_21_1 – ident: e_1_2_11_73_1 doi: 10.1038/s41591-021-01270-4 – ident: e_1_2_11_46_1 doi: 10.1126/science.abg6105 – ident: e_1_2_11_45_1 doi: 10.1001/jama.2016.4218 – ident: e_1_2_11_37_1 doi: 10.1038/d41586-020-03542-4 – ident: e_1_2_11_50_1 doi: 10.1016/S1473-3099(20)30476-X – ident: e_1_2_11_61_1 doi: 10.1093/infdis/jiy639 – ident: e_1_2_11_33_1 doi: 10.1126/science.abf0357 – ident: e_1_2_11_31_1 doi: 10.1016/S2213-2600(20)30518-X – ident: e_1_2_11_48_1 doi: 10.1038/d41586-021-00996-y – ident: e_1_2_11_74_1 doi: 10.1016/j.cell.2021.02.037 – ident: e_1_2_11_10_1 doi: 10.1038/d41586-020-02821-4 – ident: e_1_2_11_51_1 – ident: e_1_2_11_24_1 doi: 10.1086/603560 – ident: e_1_2_11_5_1 doi: 10.1101/2021.03.01.21252652 – ident: e_1_2_11_18_1 doi: 10.1038/d41586-021-00015-0 – ident: e_1_2_11_22_1 doi: 10.1016/j.chom.2021.03.009 – ident: e_1_2_11_65_1 doi: 10.1038/s41586-021-03398-2 – ident: e_1_2_11_42_1 doi: 10.1056/NEJMc2104036 – ident: e_1_2_11_19_1 doi: 10.15585/mmwr.mm695152e2 – ident: e_1_2_11_60_1 doi: 10.1016/S1473-3099(15)00362-X – ident: e_1_2_11_62_1 doi: 10.1016/S0140-6736(21)00432-3 – ident: e_1_2_11_27_1 doi: 10.1056/NEJMoa2104840 – ident: e_1_2_11_6_1 doi: 10.1056/NEJMc2102131 – ident: e_1_2_11_7_1 doi: 10.1126/science.abe6959 |
| SSID | ssj0017370 |
| Score | 2.5608177 |
| SecondaryResourceType | review_article |
| Snippet | Summary
This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization... This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2878 |
| SubjectTerms | Clinical trials COVID-19 COVID-19 infection COVID-19 vaccines Disease control Ethics Financing Immunization Lilliput mRNA Placebos prioritization seroprevalence Vaccination Vaccine development Vaccines Viruses |
| Title | COVID‐19: vaccination problems |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1462-2920.15549 https://www.ncbi.nlm.nih.gov/pubmed/33928745 https://www.proquest.com/docview/2546088335 https://www.proquest.com/docview/2520890964 https://www.proquest.com/docview/2661031323 https://pubmed.ncbi.nlm.nih.gov/PMC8209888 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Na9wwEB1CoJBLmyZp62YbHOghFxtbkm2pt7KbZVtICqUbcjOSLNElxSnd3UB7yk_ob-wvqUb-YD9IS-nNoBF47BnrjTx6D-C1q4xtheSDhRA6YrQikSA2j4grh6rCQRRB8YDzxWU-mbL311nXTYhnYRp-iH7DDTPDf68xwaWaryS5S3ESodZSjEsiHuFLaY7s-aOPPYFUWlAvF9fapqQl98Feno356-vSFtjc7plcxbJ-MRo_AdW50fSg3MTLhYr1jw2Gx__ycx8et1A1fNvE1lPYMfUBPGrEK78fQjj8cPVu9Ov-ZyrehHdS61mzsRi2GjXzI5iOzz8NJ1GrtxDpzNVdkamyjJtMWC1kronMuWSCa8msTG1CjBFMEZkm1KRVophxxVCVSyUNs8oV2Rl9Brv1bW1eQCi4NQ4qUpQ2ZoU1nDCpDLdFksk8kVUAcfe0S92SkaMmxpeyK0rQ7RLdLr3bAZz1E742PBwPmw6611e2CTkvkfY_QWHlLIDTftilEv4fkbW5XaINSbhwNR37g43DM57ukgbwvImI_n6ow5qoHhBAsRYrvQFSea-P1LPPntLb4TDBOXePxYfC31wsXY76i5f_OuEY9gh25fh9pAHsLr4tzSsHqxbqxGfOb2ntE58 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB58IHrx_ajPCh68dGnTtE28iQ_WN4iKt5KmCYpSRXcFPfkT_I3-EjNpt-wqKuKt0EnppJnmm0nyfQBrJjPWOZIPJpxLj4Y58TjRsUdMOpQnBqLwEA84Hx3HzXO6fxlddp2FKfkh6oIbRob9X2OAY0G6K8pNjBMPxZYaOCfyfhi0q3QIjE5rCqkgCa1gXGUckIreB3fzfHpA78z0BW5-3TXZjWbtdLQ7BrLjSLkL5abRbmUN-fKJ4_F_no7DaIVW3c1yeE1AnyomYajUr3yeAnfr5GJv-_31LeAb7pOQ8rqsLbqVTM3jNJzv7pxtNb1KcsGTkUm9PJVHEVMR15KLWBIRM0E5k4JqEWifKMVpRkTghyrI_Ywqkw_lsciEojozeXYUzsBAcVeoOXA508qgxRDVjWmiFSNUZIrpxI9E7IvcgUanu1NZ8ZGjLMZt2slL0O0U3U6t2w6s1w3uSyqO700XO98vrWLyMUXmfx-1lSMHVuvbJppwiUQU6q6NNsRn3KR19AcbA2ks42XowGw5JOr3CQ3cRAEBB5KewVIbIJt3753i-sqyehsoxhljplvsWPjNxdSEqb2Y_2uDFRhunh0dpod7xwcLMEJwk44tKy3CQOuhrZYMymplyzaMPgC0bhe9 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB1RqlZcaEsLhEIbJA69ZJU4TmJzQ8Bqtx-0Qt2qt8hxbIFAAcFupXLiJ_Ab-SXMOB_aBZWq6i2Sx1HG8cRvnPF7AFuYGduSyAczKXXA45IFktk0YJgOlRlCFBnTAecvB-lgxD_-TNpqQjoLU_NDdBtuFBnue00Bfl7aqSDHEGcBaS31aEmUT-ApT3GxJFx02DFIRVns9OIa44g17D5UzHPvBrML0wO0-bBochrMutWo_wKK1o-6COWkNxkXPX11j-Lxvxx9CYsNVvV36sn1CuZMtQTPavXK36_B3_36Y7h3e30TyW3_l9L6uN5Z9BuRmss3MOrvf98dBI3gQqATTLwCUyaJMIm0WqpUM5UKxaXQilsV2ZAZI3nBVBTGJirDghvMhspUFcpwW2CWncTLMF-dVWYVfCmsQawYk7Yxz6wRjKvCCJuFiUpDVXrQa0c71w0bOYlinOZtVkJu5-R27tz24EPX4bwm4viz6Xr7-vImIi9z4v0PSVk58WCza8ZYoh8kqjJnE7JhoZCY1PFHbBDQOL7L2IOVekZ0zxMj2CT5AA-ymbnSGRCX92xLdXzkOL0RiEkhBA6Lmwp_czHHIHUXa__a4T08_7bXzz8PDz69hQVGFTpuT2kd5scXE7OBEGtcvHNBdAdJaxZs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19%3A+vaccination+problems&rft.jtitle=Environmental+microbiology&rft.au=Br%C3%BCssow%2C+Harald&rft.date=2021-06-01&rft.eissn=1462-2920&rft_id=info:doi/10.1111%2F1462-2920.15549&rft_id=info%3Apmid%2F33928745&rft.externalDocID=33928745 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-2912&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-2912&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-2912&client=summon |